Agenus Presents Phase 2 BOT+BAL Melanoma Data Showing Durable Responses and Meaningful Survival in Advanced Checkpoint-Refractory Melanoma at ASCO 2026

Impact · against what's priced in

Agenus' disclosure of Phase 2 data for botensilimab and balstilimab in checkpoint-refractory melanoma provides a potential clinical catalyst. As first-disclosure data for this specific combination in this patient population, it introduces new evidence of efficacy for the company's pipeline.

AGEN+0.40

No priced-in read yet